bluebird bio, Inc. Aktie News

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the appointment of Brian Riley as President and Chief Technical Officer, Joanne Lager, MD as Chief Medical Officer, and Adrian Chaisson as Chief of Staff, further bolstering its deeply experienced management team. “I am thrilled to welcome Brian, Joanne and Adr...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer be publicly...

WASHINGTON & NEW YORK--(BUSINESS WIRE)--Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender offer commenced on March 7, 2025 to acquire all of the outstanding common stock of bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) for either (x) $3.00 per share in cash and a contingent value right per share,...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today reminds all stockholders to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of bluebird common stock by 11:59 p.m. Eastern on May 29, 2025. Stockholders that hold shares of bluebird through a broker or other nominee may be subj...

SOMERVILLE, Mass.--(BUSINESS WIRE)--As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. The parties have issued the following updated instruction...

Shares of bluebird bio Inc (NASDAQ:BLUE) surged 50% on Wednesday after the gene therapy developer announced an amended acquisition agreement with private equity firms Carlyle and SK Capital, offering shareholders a higher upfront cash payout. The revised deal includes a $5 per share cash offer, replacing a previous bid that had offered $3 per share upfront and a contingent value right (CVR) of ...

Bluebird bio and Carlyle Group and SK Capital Partners said on Wednesday that the private equity firms have offered $5 per share upfront to takeover the gene therapy maker.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), Carlyle (NASDAQ: CG) (“Carlyle”) and SK Capital Partners, LP (“SK Capital”) today announced they have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. Under the terms of the amended agreement bluebird stockholders can elect to re...